Medical technology company Stryker has completed its acquisition of Cerus Endovascular, a medical device firm focused on developing neurointerventional devices for treating intracranial aneurysms. The move is expected to expand Stryker’s portfolio of aneurysm treatment solutions, and strengthen its hemorrhagic portfolio, particularly in the field of one-and-done intrasaccular aneurysm therapy. Cerus Endovascular’s CE Marked products, including the Contour Neurovascular System and the Neqstent Coil Assisted Flow Diverter, will enable Stryker to address the growing demand for a broader range of aneurysm treatments.
Stryker (NYSE:SYK), one of the world’s leading medical technology companies, announced today that it has completed the acquisition of Cerus Endovascular Ltd., a privately held, commercial-stage, medical device company engaged in the design and development of neurointerventional devices for the treatment of intracranial aneurysms. Cerus Endovascular’s CE Marked products, the Contour Neurovascular System and the Neqstent Coil Assisted Flow Diverter, will expand Stryker’s current portfolio of aneurysm treatment solutions.
Technology for the endovascular treatment of aneurysms has been foundational to Stryker’s Neurovascular division and Cerus Endovascular’s portfolio will address the growing need for one-and-done intrasaccular aneurysm therapy.
“The acquisition of Cerus Endovascular is highly complementary to Stryker’s Neurovascular business, and strengthens our hemorrhagic portfolio globally,” stated Jim Marucci, president of Stryker’s Neurovascular division. “We look forward to working with the Cerus team to deliver on our mission of making healthcare better. Together, we will enable physicians to treat a broader range of aneurysms.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: BioSpace
